Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28083709 | 0.80 | CDK1 (0.63) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL15432579 | 0.78 | PDE4A (0.45) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5161691 | 0.78 | ADORA2A (0.63) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL5164664 | 0.77 | ADORA2A (0.61) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL15432601 | 0.76 | ADORA2A (0.35) | ADORA2AADORA2B | |
| SCHEMBL5397924 | 0.75 | ADORA2A (0.58) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL5161136 | 0.74 | ADORA2A (0.59) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL2154971 | 0.74 | CDK1 (0.56) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL8767031 | 0.73 | CCNE1 (1.00) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL5164645 | 0.72 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BTMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190330234-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330234-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, HPRT1, UMPS | CDK1 381/4885CCNB1 825/4885CCNE1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.